Estimaciones de analistas de Wall Street para Intellia Therapeutics, Inc. (NTLA): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.82 | ||
| 2026-08-06 | $-0.80 | $-0.80 | -0.1% |
| 2026-05-11 | $-0.81 | $-0.92 | +12.0% |
| 2026-02-26 | $-0.83 | $-0.99 | +16.2% |
| 2025-11-06 | $-0.92 | $-1.02 | +9.8% |
| 2025-08-07 | $-0.99 | $-1.03 | +3.9% |
| 2025-05-08 | $-1.10 | $-1.26 | +12.7% |
| 2025-02-27 | $-1.24 | $-1.32 | +6.1% |
Ratios de valoración
| Precio / Valor contable | 2.11 |
| EV / EBITDA | -4.29 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $16.5M | $26.1M | $30.4M | $43.1M | $58.0M | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M |
| Coste de Ventas | $31.8M | $67.6M | $89.1M | $108.4M | $150.4M | $6.9M | $7.6M | $9.0M | $10.3M | $15.9M |
| Beneficio Bruto | -$15.4M | -$41.5M | -$58.7M | -$65.3M | -$92.4M | $26.2M | $44.5M | $27.3M | $47.6M | $51.7M |
| I+D | $31.8M | $67.6M | $89.1M | $108.4M | $150.4M | $229.8M | $420.0M | $435.1M | $466.3M | $388.9M |
| Generales y Administrativos | $16.8M | $28.0M | $32.2M | $41.1M | $44.2M | $71.1M | $90.3M | $116.5M | $125.8M | $119.8M |
| Gastos Operativos | $48.6M | $95.7M | $121.3M | $41.1M | $44.2M | $294.0M | $502.7M | $542.6M | $581.9M | $492.7M |
| Beneficio Operativo | -$32.2M | -$69.6M | -$90.9M | -$106.4M | -$136.6M | -$267.9M | -$458.2M | -$515.3M | -$534.3M | -$441.0M |
| EBITDA | -$31.1M | -$66.6M | -$86.4M | -$100.8M | -$130.3M | -$261.0M | -$466.6M | -$472.2M | -$508.7M | -$396.8M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$31.6M | -$67.5M | -$85.3M | -$99.5M | -$134.2M | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$31.6M | -$67.5M | -$85.3M | -$99.5M | -$134.2M | -$267.9M | -$474.2M | -$481.2M | -$519.0M | -$412.7M |
| BPA | $-0.91 | $-1.88 | $-1.98 | $-1.96 | $-2.40 | $-3.78 | $-6.16 | $-5.42 | $-5.25 | $-3.81 |
| BPA Diluido | $-0.91 | $-1.88 | $-1.98 | $-1.96 | $-2.40 | $-3.78 | $-6.16 | $-5.42 | $-5.25 | $-3.81 |
| Acciones en Circulación (Diluidas) | $34.6M | $36.0M | $43.1M | $47.2M | $56.0M | $70.9M | $77.0M | $88.8M | $98.8M | $108.4M |
Precio
| Precio | $11.49 |
| Capitalización | $1.6B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: BCRX · BHVN · IMNM · PHVS · STOK · SYRE · UPB
Explorar sector: Healthcare · Biotechnology
Más secciones de NTLA: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones